Do compulsory licensing have a place in the debate on access to innovative therapies?

The access to innovative health technologies remains a main point for debate in the contemporary health policy. Finding a solution that is mutually beneficial for everyone can be extremely complicated, even impossible in certain cases. Recently, interest in regulatory practice has been the ability to enforce compulsory licensing in the pharmaceutical industry. This legal option, or rather the threat of using it, may play a role in negotiating access to new therapies. At the same time, however, it is an extreme measure with many unknown long-term consequences for the health sector and society. For more information click here.